Afobazol (Fabomotizole) Benefits and Advantages

Action research is confirmed

Afobazole (Fabomotizole): BROAD BASE OF RESEARCH - More than 80 articles describing the study the efficacy and safety Afobazol in clinical practice, involving more than 4500 patients.
Afobazol (Fabomotizole): investigated in various fields of medicine:
Cardiology
Dermatology
Neurology
pulmonology
gastroenterology
Gynecology
Psychiatry.

Afobazole Restores nerve cells

The unique formula Afobazol (INN fabomotizole) regenerates ("repairing") receptors of nerve cells and protects cells from damage, including under stress, so that they can once again do their job correctly.

The result: disappearing anxiety, tension, irritability, restlessness, there are strength and confidence, informed decisions and actions, improving the emotional background.

Afobazole operates without drowsiness
Unique Afobazol formula (INN fabomotizole) running through the natural physiological mechanisms of repair of nerve cells without affecting the sharpness and response speed of the nervous system, without effect "sleepy".

Afobazole not causes:
daytime sleepiness
reducing memory and concentration
miorelaxation
addiction
depending on
withdrawal.

Afobazol can be taken by:

drivers
people working on the complex mechanisms
wherever saving concentration required.

Thus, afobazole fits all working and living in the modern world people.

The innovative formula of Afobazole (INN fabomotizole)

Afobazol is one of the most popular and has a favorable safety profile, anti-anxiety medications in Russia. It was created in the name of the Research Institute of Pharmacology RAMS V. Zakusov headed by Academician of RAMS SB Seredenin and, unlike many traditional drugs for the treatment of anxiety, has no inhibitory effect on the central nervous system. In addition, the originality of the drug lies in the ability to restore the natural mechanism that allows the nervous system to cope with stressful workloads.

Afobazol acts quickly
Effect Afobazol seen from the first week of admission: a decline of anxiety, tension, irritability, restlessness;
The maximum effect Afobazole developed by the end of the 4th week of treatment;
The effect of receiving Afobazole persists after completion of therapy.

Afobazol Recognized by WHO experts

In 2014, the World Health Organization decided to include fabomotizole drug (Afobazol) in the class of anxiolytics (anti-anxiety medications), an international classification system for medicines - Anatomical Therapeutic Chemical Classification System, ATC.

Afobazol was created in the Research Institute of Pharmacology. VV Zakusov Medical Sciences under the leadership of academician of RAMS SB Seredenin as a result of many years of research selective anxiolytic, has effective traditional benzodiazepine tranquilizers and deprived of their inherent side effects. Afobazol efficacy and safety have been studied in numerous experimental and clinical studies.

Data on the development of the drug have been submitted for consideration by the WHO, with the result that in 2012 it was decided to award afobazole international nonproprietary name - fabomotizole. In 2013, the information obtained in the study Afobazol mechanism of action in the Russian and foreign laboratories, as well as the results of studies of its efficacy and safety have been submitted for consideration by the WHO Centre for Methodology of statistical research of drugs (The WHO Collaborating Centre for Drug Statistics Methodology), which It is the coordinating body and contributes to the wide international spread of ATS methodology. The results of the study of the mechanism of action and anxiolytic fabomotizole evidence base were discussed at the meeting of the WHO International Working Group. Submission of documentation consistent with the requirements of the WHO, which served as the basis for the assignment to the international ATC code as an anxiolytic (antianxiety) preparation (N05B - ANXIOLYTICS).
It was received during the period review submitted documentation and the proposed ATC code comments and objections. Voted ATC code was included in the ATC classification since January 2015. Afobazol OTC became the first Russian anxiolytic, received by the World Health Organization code of the international classification.